Aspergillosis on the Rise in the US: A Growing Threat to Vulnerable Populations

Aspergillosis, a fungal infection caused by Aspergillus mold, is becoming increasingly prevalent in the United States. A recent study analyzing electronic health record (EHR) data reveals a significant rise in diagnoses over the past decade, coupled with growing concerns about antifungal resistance. This trend poses a heightened risk to individuals with compromised immune systems or underlying lung conditions.

What is Aspergillosis?

Aspergillus is a common mold found both indoors and outdoors. Whereas typically harmless to those with healthy immune systems, inhaling Aspergillus spores can lead to serious infections in vulnerable individuals. These include people with lung diseases like cystic fibrosis or chronic obstructive pulmonary disease (COPD), and those with weakened immune systems due to conditions such as cancer, organ transplantation, or HIV/AIDS.

Rising Prevalence in the US

Researchers at the University of California, Berkeley, analyzed EHR data from over 76 million US patients across 142 health systems between 2013 and 2023. Their findings, published in Open Forum Infectious Diseases, showed a population-based prevalence of 15.26 diagnoses per 100,000 person-years. Notably, diagnoses increased by more than 5% annually before the COVID-19 pandemic.

Types of Aspergillosis and Severity

There are several forms of aspergillosis, ranging in severity:

• Allergic Bronchopulmonary Aspergillosis (ABPA): An allergic reaction to the fungus, primarily affecting individuals with asthma or cystic fibrosis.
• Chronic Pulmonary Aspergillosis: A long-term infection that can develop slowly, often in individuals with pre-existing lung conditions.
• Invasive Aspergillosis: The most severe form, where the fungus spreads through the bloodstream to other organs. This is often fatal, with an overall death rate of approximately 20%.

The Challenge of Antifungal Resistance

Adding to the concern is the increasing resistance of Aspergillus to antifungal medications, particularly triazoles. A study reviewing clinical isolates from Dutch hospitals over nearly 30 years found that 15.6% harbored mutations conferring triazole resistance . This resistance is linked to the widespread use of agricultural fungicides and is making treatment more difficult. In a review of 59 patients with invasive aspergillosis, 22% had triazole-resistant cases.

Global Impact and Surveillance Gaps

Globally, an estimated 250,000 cases of invasive aspergillosis and over 3 million cases of chronic pulmonary aspergillosis occur annually. However, until recently, US-specific trends were unclear due to a lack of comprehensive surveillance. The recent study utilizing EHR data represents a significant step towards better understanding the epidemiology of aspergillosis in the United States.

Looking Ahead

The rising prevalence of aspergillosis and the emergence of antifungal resistance highlight the need for improved surveillance, early diagnosis, and the development of new treatment strategies. Further research is crucial to understand the factors driving this increase and to protect vulnerable populations from this potentially life-threatening infection.